
|Videos|March 20, 2019
Ongoing Research for New Frontline Treatments in Follicular Lymphoma
Author(s)Carla Casulo, MD
Carla Casulo, MD, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma.
Advertisement
Carla Casulo, MD, associate professor in the department of medicine at the University of Rochester Medical Center, discusses recent research for new frontline options for patients with newly diagnosed follicular lymphoma (FL).
A large randomized study looked at frontline treatment with the combination lenalidomide (Revlimid) plus rituximab (Rituxan) compared to standard chemotherapy. The study aimed to establish non-inferiority, but it was found that the 2 regimens were not dramatically different, says Casulo.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications
2
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
3
Long-Term ECHO Data Support Concurrent Acalabrutinib/BR in MCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































